Car T Cells and a Good \201cbeating\201d for Breast Cancers

A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer

AI Ali, M Wang, B Von Scheidt, PM Dominguez, AJ Harrison, DGM Tantalo, J Kang, AJ Oliver, JD Chan, X Du, Y Bai, B Lee, RW Johnstone, PK Darcy, MH Kershaw, CY Slaney

2021-11-15

Purpose: In this article, we describe a combination chimeric antigen receptor (CAR) T-cell therapy that eradicated the majority of..

Cross-talk between tumors at anatomically distinct sites

AJ Oliver, PK Darcy, JA Trapani, MH Kershaw, CY Slaney

2021-01-01

Cancer tissue is not homogenous, and individual metastases at different anatomical locations can differ from the primary tumor and..

Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers

AJ Harrison, X Du, B Von Scheidt, MH Kershaw, CY Slaney

2021-01-01

Co-stimulation is a fundamental component of T cell biology and plays a key role in determining the quality of T cell proliferatio..

Will next-generation immunotherapy overcome the intrinsic diversity and low immunogenicity of sarcomas to improve clinical benefit?

HY Chew, V Chan, F Simpson, R Dolcetti

2020-11-01

Sarcomas are a rare type of a heterogeneous group of tumours arising from mesenchymal cells that form connective tissues. Surgery ..

Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells

JD Chan, B von Scheidt, B Zeng, AJ Oliver, AS Davey, AI Ali, R Thomas, JA Trapani, PK Darcy, MH Kershaw, R Dolcetti, CY Slaney

2020-01-01

Objectives: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is a form of cancer immunotherapy that has achie..